Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera (NASDAQ:NTRA) announced a major expansion at its North Austin headquarters, adding a dedicated sequencing facility and new lab space to support rapid growth.
The facility is expected to have the largest sequencing capacity in the world, meeting rising demand, especially in oncology, where testing volumes grew over 54% year-over-year in Q1 2026.
Natera’s Signatera test is used by more than 50% of U.S. oncologists, and Signatera CDx recently became the first FDA-approved companion diagnostic in molecular residual disease testing. The expansion is expected to create up to 400 new jobs across professional, laboratory, and operational roles while supporting hundreds of ongoing clinical trials and research collaborations.
Natera (NASDAQ:NTRA) reported that the EXPAND clinical trial of its Fetal Focus™ single-gene noninvasive prenatal test (NIPT) has enrolled over 2,000 patients, more than doubling enrollment in the past 12 months.
EXPAND is a prospective, blinded, multi-site study assessing Fetal Focus, which evaluates 21 genes linked to serious, early-onset conditions and uses LinkedSNP™ technology. Early EXPAND data showed strong clinical performance and accurate detection in 5 of 5 difficult homozygous cases.
Natera (NASDAQ:NTRA) announced FDA approval of Signatera CDx as a companion diagnostic for adjuvant atezolizumab (Tecentriq) immunotherapy in muscle-invasive bladder cancer (MIBC). This is the first FDA-approved blood-based MRD companion diagnostic.
According to Natera, IMvigor011 Phase III data showed MRD-positive patients on immunotherapy had improved DFS and OS, while MRD-negative patients achieved 97% 2-year OS without adjuvant therapy. Signatera is supported by 185+ publications and Medicare coverage across multiple cancer types.
Natera (NASDAQ: NTRA) reported Q1 2026 results: $696.6M revenue, up 38.8% year-over-year; processed 1,013,600 tests (up 18.5%); gross margin of 64.7%. Oncology tests rose 54.4% to 258,900. Net loss was $85.1M (−$0.60/share). Company raised 2026 revenue guidance to $2.74B–$2.82B and expects positive net cash inflow.
Natera (NASDAQ: NTRA) will release results for its first quarter ended March 31, 2026, after market close on May 7, 2026. A conference call and webcast will follow at 1:30 p.m. PT (4:30 p.m. ET), with replay available at the company's investor site.
Dial-in, conference ID and webcast links will be provided for investors and analysts to access the live presentation and Q&A.
Natera (NASDAQ: NTRA) will feature Prospera in 17 abstracts (six oral) at ISHLT 2026, highlighting heart and lung transplant applications. Key findings cite Prospera’s ability to predict 1-year adverse outcomes, influence clinical decisions in >30% of cases, reduce false positives with DQS, and detect CLAD, infection, and reflux-related injury.
Natera highlighted Allogene Therapeutics' interim futility analysis from the ALPHA3 trial (ALLO) on April 13, 2026. The analysis reported 58.3% MRD clearance with cema-cel and a median 97.7% ctDNA decrease at Day 45 versus a 26.6% median increase in observation.
The trial uses Natera's CLARITY MRD assay to randomize MRD-positive LBCL patients to cema-cel or observation; results are interim and final clinical outcomes remain pending.
Natera (NASDAQ: NTRA) said a Delaware federal judge on April 6, 2026 awarded Natera a 30% ongoing royalty on post-injunction revenues from infringing MRD-related product sales that fall within exceptions to a Nov 21, 2023 injunction.
The jury’s prior 20.5% effective royalty on pre-injunction revenues remains unchanged, and the court upheld validity of all three asserted MRD patents. Natera noted it holds over 650 issued or pending patents, including a portfolio of MRD patents.
Natera (NASDAQ: NTRA) will present 20 abstracts at AACR Annual Meeting April 17–22, 2026, spanning AI, ctDNA decision-making, MRD and real-world evidence.
Key data: models trained on >45,000 colorectal cases; AI AUROC 0.98 (MSI) and 0.93 (BRAF V600E); breast ML precision 93.5%/recall 91.1%; ctDNA study of 465 MSI-H metastatic CRC patients showed ~40% early ctDNA clearance and 3-year OS of 96% for early Signatera-negative patients.
Natera (NASDAQ: NTRA) published a prospective study in Clinical Cancer Research showing Signatera MRD testing identified older women with early-stage ER+/HER2- breast cancer who could forgo surgery and remain progression-free while receiving primary endocrine therapy (pET).
Key findings: 68% baseline MRD-negative (0 progressions), 100% baseline negative predictive value, and 100% longitudinal sensitivity for progression detection; 43 patients enrolled, monitored every 3–6 months.